TMJ Concepts Patient Fitted Temporomandibular Joint (TMJ) Reconstruction Prosthesis System
Stryker Leibinger GmbH & Co. KG · Decision date Jul 23, 2025
What did the FDA approve?
FDA records P980052/S016 as a supplement to PMA P980052, with the supplement type “Special (Immediate Track)”. The recorded decision is approval, dated Jul 23, 2025.
FDA approval order statement
to modify the method of inspection of the articular surface of the Fossa component to utilize the MarSurf CM Explorer Microscope
- Regulatory pathway
- PMA supplement
- Supplement type
- Special (Immediate Track)
- Clinical specialty
- Dental
- Decision date
- Jul 23, 2025
- FDA change category
- Process Change - Manufacturer/Sterilizer/Packager/Supplier
Regulatory record facts
- Identifier
- P980052/S016
- Regulatory pathway
- PMA supplement
- Applicant
- Stryker Leibinger GmbH & Co. KG
- Product code
- LZD
- Decision code
- APPR
- Decision date
- Jul 23, 2025
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Joint, temporomandibular, implant.
- Applicant
- Stryker Leibinger GmbH & Co. KG
- Product code
- LZD
- FDA device class
- 3
Review the original FDA PMA listing for the original approval scope and linked supplements.
FDA decision timeline
P980052/S016 received
Application receipt date recorded by FDA.
P980052/S016 · FDA decision
Special (Immediate Track)
P980052/S017 · Related supplement
TMJ Concepts Patient-Fitted TMJ Reconstruction Prosthesis
Timeline entries are records held by MedtechLedger for P980052. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P980052
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Stryker Leibinger GmbH & Co. KG | PMA supplement | Mar 6, 2026 | FDA |
Explore the linked device profile
Other records with product code LZD
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
Total Temporomandibular Joint Replacement SystemP020016/S013 | BIOMET MICROFIXATION, INC | PMA supplement | Feb 19, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Stryker Leibinger GmbH & Co. KG
- Headquarters
- Not reported
- Brand website
- stryker.com
- FDA applicant address
- Boetzinger Strasse 41, D-7911, Freiburg, D-7911
Sources and methodology
- Original FDA record: P980052/S016
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 21, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records
